These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. [The metabolic effects of beta-receptor blockers. What is of practical importance in antihypertensive therapy?]. Sawicki PT; Berger M Dtsch Med Wochenschr; 1992 May; 117(22):875-9. PubMed ID: 1350758 [No Abstract] [Full Text] [Related]
44. Strategies for the development of new PPAR agonists in diabetes. Cavender MA; Nicholls SJ; Lincoff AM Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S32-7. PubMed ID: 20489419 [TBL] [Abstract][Full Text] [Related]
45. [Insulin resistance. A syndrome responsible for various cardiovascular diseases]. Golay A Schweiz Rundsch Med Prax; 1992 Jan; 81(3):45-8. PubMed ID: 1733002 [TBL] [Abstract][Full Text] [Related]
46. [Treatment for hypertension with metabolic disorders (DM etc)]. Shimamoto K; Miura T Nihon Rinsho; 2006 Aug; 64 Suppl 6():513-9. PubMed ID: 16981585 [No Abstract] [Full Text] [Related]
47. Leptin and the clinical cardiovascular risk. Singh M; Bedi US; Singh PP; Arora R; Khosla S Int J Cardiol; 2010 Apr; 140(3):266-71. PubMed ID: 19944469 [TBL] [Abstract][Full Text] [Related]
48. Elderly veterans at risk for nutrition-related cardiovascular disease. Moran MB; Naughton BJ; Hughes SL J Am Diet Assoc; 1992 Jul; 92(7):863-5. PubMed ID: 1624657 [No Abstract] [Full Text] [Related]
49. Current pharmacotherapeutic concepts for the treatment of cardiovascular disease in diabetics. Highlander P; Shaw GP Ther Adv Cardiovasc Dis; 2010 Feb; 4(1):43-54. PubMed ID: 19965897 [TBL] [Abstract][Full Text] [Related]
50. Metabolic neutrality in nitrendipine therapy. Mancini M; Marotta T; Ferrara LA J Cardiovasc Pharmacol; 1991; 18 Suppl 1():S30-3. PubMed ID: 1723452 [TBL] [Abstract][Full Text] [Related]
51. [Abdominal obesity. The metabolic syndrome, arteriosclerosis and mortality]. Wirth A; Krone W Dtsch Med Wochenschr; 1993 Apr; 118(16):595-601. PubMed ID: 8482234 [No Abstract] [Full Text] [Related]
52. Physical activity and the metabolic cardiovascular syndrome. Westheim A; Os I J Cardiovasc Pharmacol; 1992; 20 Suppl 8():S49-53. PubMed ID: 1283770 [TBL] [Abstract][Full Text] [Related]
53. Should we evaluate for cardiovascular disease in patients with Cushing's syndrome? Fallo F; Sonino N Clin Endocrinol (Oxf); 2009 Dec; 71(6):768-71. PubMed ID: 19508589 [TBL] [Abstract][Full Text] [Related]
54. [The metabolic X syndrome--4 case reports]. Ivković-Lazar T; Lepsanović L; Babić L; Stokić E; Tesic D; Medić-Stojanoska M Med Pregl; 1992; 45(5-6):210-4. PubMed ID: 1365060 [TBL] [Abstract][Full Text] [Related]
55. [Cardiovascular risk management in the hypertensive patient]. Pereira S Acta Med Port; 2010; 23(2):223-6. PubMed ID: 20470469 [TBL] [Abstract][Full Text] [Related]
56. Introductory remarks. Velasco M; Bermúdez V; Israili ZH; Hernández-Hernández R Am J Ther; 2010; 17(3):236. PubMed ID: 20479578 [No Abstract] [Full Text] [Related]
57. [Treatment of hypertension associated with diabetes mellitus]. Ishii C; Negishi K; Katayama S Nihon Rinsho; 1997 Nov; 55 Suppl():769-75. PubMed ID: 9434562 [No Abstract] [Full Text] [Related]
58. [The effects of the physical training on the hypertensive patients with glycoregulation disorder]. Chiriac S; Cozma CD; Jerca O; Pandele GI Rev Med Chir Soc Med Nat Iasi; 2003; 107(1):108-12. PubMed ID: 14755979 [TBL] [Abstract][Full Text] [Related]
59. Effects of a healthy Nordic diet on cardiovascular risk factors in hypercholesterolaemic subjects: a randomized controlled trial (NORDIET). Adamsson V; Reumark A; Fredriksson IB; Hammarström E; Vessby B; Johansson G; Risérus U J Intern Med; 2011 Feb; 269(2):150-9. PubMed ID: 20964740 [TBL] [Abstract][Full Text] [Related]